Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

BIIB017

BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT01337427 - Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis | Biotech Hunter | Biotech Hunter